Dechra Pharmaceuticals plc with ticker (LON:DPH) now has a potential downside of -27.5% according to Liberum Capital.
Liberum Capital set a target price of 3,960 GBX for the company, which when compared to the Dechra Pharmaceuticals plc share price of 5,050 GBX at opening today (09/12/2021) indicates a potential downside of -27.5%. Trading has ranged between 3,132 (52 week low) and 5,525 (52 week high) with an average of 326,029 shares exchanging hands daily. The market capitalisation at the time of writing is £5,466,065,790.
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.